Document Classification

Section Type: RESULTS

Text: Following administration of the first dose of the quadrivalent HPV-6 / 11/16/18 vaccine, the anti-HPV-16 geometric mean titer among monovalent HPV-16 vaccine recipients (GMT = 5024. 0 milli-Merck units per milliliter [mMU/mL] ; 95 % confidence interval [CI] : 2710. 1, 9313. 6 mMU/mL) substantially exceeded that among the placebo recipients (GMT = 136. 1 ; 95 % CI : 78. 5, 235. 8 mMU/mL ; p < 0. 01) and their own highest anti-HPV-16 response observed during the original trial (GMT at month 7 of the original trial = 1552. 7 mMU/mL ; 95 % CI : 1072. 6, 2247. 7 mMU/mL ; p < 0. 01).